Generation Bio, Vir partner for mAbs against COVID-9

By The Science Advisory Board staff writers

March 30, 2020 -- Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.

The collaboration will allow Generation Bio's gene therapy platform, which delivers genetic information to cells without the use of adeno-associated viruses, to be combined with Vir's neutralizing antibodies, the two firms said.

Vir's leading antibody was developed from a patient who recovered from SARS-CoV-1 and could neutralize SARS-CoV-2, according to Generation Bio and Vir.

If you like this content, please share it with a colleague!

Related Reading

Dynavax, Clover partner for protein-based COVID-19 vaccine
A new research collaboration between Dynavax Technologies and Clover Biopharmaceuticals aims to develop a vaccine candidate to prevent COVID-19. The partnership,...

Better flu treatments on the way thanks to the discovery of broadly protective antibodies
Research from the National Institutes of Allergy and Infectious Diseases (NIAID) isolated the antibodies from a person sick with the flu five days after...

NIH Invests $100 million in cures for sickle cell disease and HIV
The National Institutes of Health (HIH) announced that it plans to invest at least $100 million over the next four years towards developing affordable,...

Vaccine in development against hypervirulent Klebsiella
Concerns arising over the development of hypervirulent strains of Klebsiella pneumoniae have led researchers to develop an entirely new vaccine to protect...

Overlooked benefits of using polyclonal antibodies
The benefits of polyclonal antibodies as tools for assay-specific target discovery and detection are numerous. As the future of basic research, diagnostics...